activity
20232026
collaborators
Showing 2026Show all

9 papers · 1 filter

stat.ME2026

BOP2-ENR: a Bayesian optimal phase II design for adaptive enrichment with family-wise error rate control and a bound on joint-claim power

Kentaro Takeda, Belay B. Yimer, Masahiro Kojima

The Bayesian optimal phase II (BOP2) design accommodates simple and complex endpoints but does not address biomarker-guided enrichment or multiplicity control across pooled and sub…

stat.ME2026

Feedback-Aware Tuning of Recursive Q-Learning

Masahiro Kojima

Model choice in backward Q-learning is recursive because a later-stage choice changes the response supplied to an earlier regression and can alter its model-comparison statistic. S…

stat.ME2026

Finite-Boundary Reduction and Exact Verification of Strong Familywise Error in Active-Count-Coupled Multi-Arm Efficacy-Toxicity Monitoring

Masahiro Kojima, Hisato Sunami, Kentaro Takeda

Randomized dose-optimization trials may screen several candidate doses using binary efficacy and toxicity outcomes. A dose is inadmissible if efficacy is insufficient or toxicity i…

stat.ME2026

A staggered seamless dose-optimization design for co-developing monotherapy and combination therapy

Masahiro Kojima, Kentaro Takeda, Ying Yuan

Contemporary oncology drug development increasingly requires efficient dose-optimization strategies that evaluate monotherapy (Mono) and combination therapy (Combo) while balancing…

stat.ME2026

A seamless dose-optimization design for monotherapy and combination therapy

Kentaro Takeda, Masahiro Kojima

The emergence of molecular-targeted agents and immune-oncology therapies has fundamentally transformed oncology drug development, necessitating evolution beyond traditional dose-fi…

stat.ME2026

A Globally Calibrated Bayesian Optimal Phase II Design for Adaptive Enrichment Trials

Masahiro Kojima, Hisato Sunami, Masaaki Kuriki

Adaptive enrichment allows development of an experimental treatment to continue when its activity is insufficient in an all-comer population but remains promising in a prespecified…

stat.ME2026

Fast Power Evaluation under Biased-Coin Minimization: Sampling and Randomization Calibration

Masahiro Kojima

Design-stage power and sample-size evaluation under biased-coin minimization can be computationally intensive when a prespecified randomization test is reproduced within every simu…

stat.ME2026

Outcome-blinded sample size re-estimation for externally controlled single-arm trials using baseline covariates

Keisuke Hanada, Masahiro Kojima

Externally controlled single-arm trials provide an option when limited patient populations or ethical constraints make concurrent randomized controls impractical, including in rare…

stat.ME2026

Hybrid Non-informative and Informative Prior Model-assisted Designs for Mid-trial Dose Insertion

Kana Yamada, Hisato Sunami, Kentaro Takeda +2

In oncology phase I trials, model-assisted designs have been increasingly adopted because they enable adaptive yet operationally simple dose adjustment based on accumulating safety…